Topic: Health

Researchers at Duke-NUS Medical School found a molecular switch that determines whether pancreatic cancer cells respond to chemotherapy or resist it. This discovery could lead to more effective treatments for patients with this aggressive disease.

Pancreatic cancer is one of the deadliest cancers worldwide, and treatment options are limited. Scientists have identified two main molecular subtypes of pancreatic cancer: classical and basal. Tumors in the classical subtype tend to be more organized at the cellular level and respond better to treatment.

The research team focused on a gene called GATA6, which helps maintain pancreatic cancer cells in the more structured and less aggressive classical state. When GATA6 levels are high, tumors tend to grow in a more organized way and are more likely to respond to chemotherapy. However, when GATA6 levels fall, cells lose their structure, become more aggressive, and are harder to treat.

The team discovered that the switch between these two states is controlled by a chain of signals inside pancreatic cancer cells. A gene called KRAS, which is mutated in nearly all pancreatic cancers, sends constant growth signals that drive tumor development. These signals pass through a partner protein known as ERK, which relays the instructions further inside the cell.

The researchers found that blocking the KRAS and ERK pathway lifts this suppression, allowing GATA6 levels to rise again. This causes cancer cells to shift back toward the more organized state and regain sensitivity to chemotherapy.

Combining targeted therapies with standard chemotherapy may improve outcomes for patients whose tumors no longer respond to treatment.

Why It Matters

This discovery could lead to more effective treatments for pancreatic cancer, which is a major health concern in India. With early detection and proper treatment, more patients can survive this aggressive disease.

Key Facts

• Pancreatic cancer is one of the deadliest cancers worldwide.
• The classical subtype of pancreatic cancer tends to be more organized at the cellular level and responds better to treatment.
• GATA6 levels determine whether pancreatic cancer cells respond to chemotherapy or resist it.
• Blocking the KRAS and ERK pathway can lift this suppression, allowing GATA6 levels to rise again.

Key Terms

KRAS

A gene that is mutated in nearly all pancreatic cancers and drives tumor development

Implications

This discovery could lead to more effective treatments for pancreatic cancer, which is a major health concern in India. With early detection and proper treatment, more patients can survive this aggressive disease.